Sequential Treatment of Cabozantinib or Cabozantinib With Nivolumab for Advanced Renal Cell Carcinoma (RCC)
Status:
Recruiting
Trial end date:
2027-12-31
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to learn about the effects of a higher dose of
cabozantinib or the effects of cabozantinib-nivolumab combination in patients with advanced
renal cell carcinoma who have progressed on or after receiving cabozantinib treatment. The
study will have two parts or "cohorts".
- Cohort 1: cabozantinib 80mg daily
- Cohort 2: cabozantinib 40mg daily with nivolumab The cohort assignment will be
determined by investigator, based on how much cabozantinib the participant is able to
safely receive.